We are live on
!
Find out more
BC
Broadwood Capital Portfolio holdings
AUM
$1.42B
1-Year Est. Return
34.72%
This Fund
S&P 500
This Quarter
Est. Return
-13.34%
1 Year Est. Return
+34.72%
3 Year Est. Return
+45.97%
5 Year Est. Return
+44.27%
10 Year Est. Return
+866.96%
AUM
$1.42B
AUM Growth
-$283M
(-17%)
Cap. Flow
-$30.8M
Cap. Flow
% of AUM
-2.17%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
12
New
–
Increased
2
Reduced
1
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
STAAR Surgical
STAA
|
+$21.1M |
| 2 |
IMDX
Insight Molecular Diagnostics
IMDX
|
+$3.03M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Monster Beverage
MNST
|
+$7.19M |
| 2 |
Serina Therapeutics
SER
|
+$104K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Staples | 41.41% |
| 2 | Healthcare | 29.53% |
| 3 | Industrials | 20.76% |
Similar funds
PTC
NI
CBA
KC
EWS
IHG
SCM
PPC
Broadwood Capital's Q1 2026 Portfolio in Review
As of Q1 2026, Broadwood Capital held 12 positions worth $1.42B, down 17% from $1.7B the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Broadwood Capital's Q1 2026 filing shows 2 increased, 1 reduced and 6 closed positions. The largest sale was Monster Beverage, an estimated $7.19M.
By sector, the portfolio is most concentrated in Consumer Staples at 41% of assets, up from 37% a quarter earlier, followed by Healthcare and Industrials.
- Broadwood Capital added most to STAAR Surgical in Q1 2026, an estimated $21.1M increase.
- Broadwood Capital's biggest Q1 2026 reduction was Monster Beverage, cutting an estimated $7.19M.
- Broadwood Capital fully exited Serina Therapeutics in Q1 2026, selling an estimated $104K.
- Broadwood Capital's ten largest holdings make up 100% of its $1.42B portfolio in Q1 2026.
- Broadwood Capital opened 0 new positions and closed 6 in Q1 2026.
- Broadwood Capital's portfolio value fell 17% quarter-over-quarter to $1.42B.
Based on Broadwood Capital's 13F filing for Q1 2026, filed 15 May 2026.